A meta-analysis[46] evaluated the efficacy of ICIs utilized in advanced-stage, second-line EGFR-mutated NSCLC, encompassing Checkmate 057, Keynote 010, and POPLAR trials, demonstrating that ICIs, when compared with chemotherapy, did not confer significant OS benefits for patients with EGFR mutations (P = 0.42). Here, EGFR is linked to non-small cell lung carcinoma.